Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab Long-term Safety Extension Study
NCT04638647Phase 4Recruiting
- Sponsor
- Novartis
- Start
- Dec 2020
- Primary completion
- Jan 2030
- Countries
- 20
01
Overview
Phase 4, open-label, single-arm trial of secukinumab in autoimmune disease and inflammation, sponsored by Novartis. Primary endpoint: Adverse Events and Serious Adverse Events up to 2 years. Started Dec 2020; status: recruiting.
02
Drugs
secukinumab
03
Conditions
autoimmune diseaseinflammation
Beyond the preview
Go deeper on NCT04638647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04638647.